Treatment of locally advanced gastric cancer with Tislelizumab and chemotherapy

A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer with SOX Plus Tislelizumab Combined with HIPEC

This study is testing if a new treatment combining Tislelizumab and chemotherapy can help people with locally advanced gastric cancer live longer and have fewer problems after treatment.

Quick facts

• Study type: Observational
• Enrollment: 122 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Southwest Hospital, China (Academic / other)
• Drugs / interventions: chemotherapy, immunotherapy, radiation, prednisone, Tislelizumab
• Locations: 2 sites (Chongqing, Chongqing Municipality and 1 other locations)
• Trial ID: NCT06760858 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the efficacy and safety of Tislelizumab in combination with the SOX chemotherapy regimen and HIPEC for patients with locally advanced gastric cancer. The study focuses on assessing the 3-year disease-free survival and major pathological response among participants. Patients will receive the treatment and be monitored for various outcomes, including overall survival and incidence of adverse reactions. The trial aims to provide insights into the effectiveness of this combined treatment approach.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 to 80 with newly diagnosed Her-2 negative gastric adenocarcinoma who have not received prior cancer treatments.

Not a fit: Patients with obstructed, perforated, or bleeding gastric cancer, or those with prior chemotherapy or radiotherapy, may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve disease-free survival rates for patients with locally advanced gastric cancer.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in using immunotherapy combined with chemotherapy for various cancers.

Eligibility criteria

Inclusion Criteria:

* Patients with newly diagnosed Her-2 negative gastric adenocarcinoma, with no prior chemotherapy, radiotherapy, or other anti-cancer treatments before the start of the clinical trial.
* Age between 18 to 80 years old, Eastern Cooperative Oncology Group (ECOG) performance status: 0-1.
* Staging according to the American Joint Committee on Cancer (AJCC) 8th edition is T4aNxM0, without obstruction, perforation, or bleeding risk.
* Good bone marrow reserve function, with the following blood criteria: white blood cell count ≥3×10\^9/L, neutrophils ≥1.5×10\^9/L, platelet count ≥100×10\^9/L, hemoglobin ≥90 g/L.
* Good organ function, with the following biochemical criteria: aspartate aminotransferase (AST) ≤2.5×upper limit of normal (ULN), alanine aminotransferase (ALT) ≤2.5×ULN, serum total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min.
* International normalized ratio (INR) ≤1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 times ULN.
* Urine protein \<2+, if urine protein ≥2+ then 24-hour urine protein quantification must be ≤1g.
* Consent to provide blood and tissue samples.
* Expected survival of more than 3 months.
* Female subjects agree to strict contraception; male subjects with partners of childbearing potential agree to use effective contraception during the study period.
* Voluntarily sign the informed consent form, willing and able to comply with planned visits, study treatments, laboratory tests, and other trial procedures.

Exclusion Criteria:

* Participants who have been enrolled in any other drug clinical trial or have participated in any drug clinical trial within the last month.
* Any anti-cancer treatments (chemotherapy, radiotherapy, surgery, immunotherapy, biotherapy, chemoembolization) other than the study medication (palliative external beam radiation for non-target lesions is allowed).
* Prior use of similar chemotherapy drugs or immune checkpoint inhibitors.
* Presence of metastatic lesions in the liver, lungs, para-aortic lymph nodes, bones, brain, adrenal glands, or pelvic and abdominal cavity.
* Gastrointestinal perforation, obstruction, or uncontrollable diarrhea within 6 months prior to enrollment.
* Other untreated or concurrent tumors, except for cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors. Patients with tumors that have been cured and have no evidence of disease for more than 5 years may be included. All other tumors must have been treated at least 5 years prior to enrollment.
* Symptomatic meningiomas：
* History of active autoimmune diseases or refractory autoimmune diseases.
* Received corticosteroids (\>10mg/day prednisone or equivalent dose of steroids) or other systemic immunosuppressive therapy within 14 days prior to enrollment, excluding the following treatments: steroid hormone replacement therapy (≤10mg/day); local steroid therapy; and short-term prophylactic steroid therapy for allergies or nausea and vomiting.
* History of HIV infection or active hepatitis B/C virus infection.
* Persistent \> Grade 2 bacterial, fungal, viral infections.
* Active or clinically significant cardiac disease:
* Congestive heart failure \> New York Heart Association (NYHA) Class II;
* Active coronary artery disease;
* Arrhythmias requiring treatment other than beta-blockers or digoxin;
* Unstable angina (angina symptoms at rest), new-onset angina within 3 months prior to enrollment, or unhealed wounds, ulcers, or fractures due to myocardial infarction within 6 months prior to enrollment.
* Patients with renal failure requiring hemodialysis or peritoneal dialysis.
* Patients requiring medication for epilepsy.
* History of organ transplantation (including corneal transplants).
* Allergy to the study medication or similar drugs, or suspected allergies.
* Pregnant or breastfeeding women.
* Major surgery, open biopsy, or significant traumatic surgery within 4 weeks prior to recruitment.
* History of vaccination within 4 weeks prior to enrollment.
* Patients deemed unsuitable for the study by the investigator.

Where this trial is running

Chongqing, Chongqing Municipality and 1 other locations

• The Southwest hospital of AMU — Chongqing, Chongqing Municipality, China (Recruiting)
• The Southwest hospital of AMU — Chongqing, Chongqing Municipality, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Yan Shi, doctor

Conditions Gastric Cancer, Gastroesophageal Junction Cancer; neoadjuvant chemotherapy